Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP 14 vs R-CHOP 21 +/- Darbepoetin Alfa in Elderly DLBCL
NCT00144755Phase 3Completed
- Sponsor
- Lymphoma Study Association
- Start
- Dec 2003
- Primary completion
- Dec 2012
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in diffuse large B-cell lymphoma (DLBCL) and anemia (4 arms), sponsored by Lymphoma Study Association. Primary endpoint: Event-Free Survival at 8 years. Started Dec 2003; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
diffuse large B-cell lymphoma (DLBCL)anemia
Beyond the preview
Go deeper on NCT00144755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144755.